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Global climate change is challenging for the pharmaceutical industry as it is for all other industries, where they 
have to select packaging that keep their products stable. The aim of this study was to investigate the effect of a 
tropical environment on pharmaceutical preparations in repackaged containers using the drug in the original 
container as control. This study concluded that in a tropical environment, some immediate release medications, 
underwent significant changes in their physical characteristics, and a less significant loss of efficacy. Bacterial 
and fungal growth inside and outside packages used in re-packaging and on the tablet surface occurred after four 
weeks. To improve patient adherence, multiple-dose compartment dose administration aids are used to alleviate 
the risk of patients’ non-adherence due to the regimen complexity of chronic disease therapy. On discharge, 
hospitals dispense between three and seven days’ supply of medication, usually in plastic bottles or sometimes 
plastic bags, as a cost-saving measure. Re-packaging of medications is currently common practice, to 
personalizes medication for individual patients. This preliminary study demonstrated that products stored in 
tropical conditions, changed in their characteristics and gained microbial contamination during the process or 
repacking. Further research is required to fully characterize the problem. 
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INTRODUCTION 
 
Packaging is one of the largest industries in the world. 
All producers of goods for human consumption, including the 
pharmaceutical industry, face challenges in providing packaging 
that keeps products attractive to consumers but protected from 
the climate. Storage conditions for pharmaceuticals are usually 
standardized to suit the formulation however, this only apply to 
the product in manufacturer containers or packs (Liu et al., 2011; 
Feng et al., 2014). To improve patient adherence, multiple-dose 
compartment administration aids (re-usable or disposable) are  
used to alleviate the risk of non-adherence due to the              
complexity   of   chronic  disease therapy, poor health literacy or 
cognitive impairment. Additionally, hospitals only dispense 
between three and seven days’ medication to save costs, usually                    
.   
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in plastic bottles or bags. The stability of medications and possible 
microbial growth on the solid form (tablets or capsules) when 
repackaged out of the original container into another during 
dispensing is not guaranteed by the manufacturer. This study 
investigated the stability of pharmaceuticals in different packaging 
when used to improve patient adherence or for partial supply from 
a full pack. Currently, 85% of manufacturers in Europe use blister 
packs (Pilchik, 2000a; Pilchik, 2000b) whereas in the United States 
of America (USA) the majority of over the counter and prescribed 
medications are repackaged from large containers of up to 1000 
tablets into smaller bottles according to the required quantity, 
either manually or by robots (Zadbuke et al., 2013). The use of 
blister packaging is becoming more recognized in the USA as it 
can provide product integrity, product protection, tamper evidence, 
reduced possibility of accidental use and patient adherence.  
 The microbial quality of pharmaceuticals is influenced by 
the process used, the environment and the quality of the raw             
. 
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materials used during formulation. The incidence of medication 
contamination, especially those required to be sterile, is known to 
be related to the nature of the ingredients (whether natural or 
synthetic), the quality of the vehicle used to manufacture the 
medications, the container used and the training, care and attitude 
of personnel involved in their handling (Okunlola, 2007).  
Most raw materials for pharmaceutical excipients allow 
microbial growth, depending on the nutritional properties and 
moisture content (Gunar, 2011). Accordingly, as part of 
medications quality assurance process, the microbial presence or 
contamination load, must be documented. In many tropical 
countries, pharmaceutical raw materials and final products are 
subject to be stored in-transit or during use under uncontrolled 
conditions, and may be dispensed in non-protective packaging or 
even without any packaging at all, where the average temperature 
is 30°C and the average RH is >75% (Gunar, 2011). Dispensing of 
tablets and capsules from large packs is a common practice in 
hospital pharmacies, clinics and nursing homes. Some open large 
containers take an average of four weeks to be completely 
dispensed, depending on demand (Akerele and Ukoh, 2011). 
Unlike the rich literature around microbial contamination in 
injectable liquids, few studies have been conducted investigating 
the bioburden on solid oral formulations. Microbiological quality 
parameters of drugs are closely associated with the safety of their 
useand the route by which they will be administered (Okunlola, 
2007). Drug contamination may occur at any stage during the 
manufacturing process from the equipment used, raw materials, 
excipients, method of storage, transportation stages, water use in 
manufacture, air ventilation or personnel (Department of Health 
and Human Services US, 2004). Stability testing is a routine 
procedure performed on medicinal substances and products, and is 
employed at various stages of product development. In early 
stages, accelerated stability testing (at relatively high temperatures 
and/or humidity) is used to determine the type of degradation that 
may be found after long-term storage (International Council for 
Harmonization Expert Working Group, 2009; Feng et al., 2015). 
Shelf life is the time during which the product, if stored 
appropriately as per the manufacturer’s instructions, will retain 
fitness for use (British Pharmacopoeia vol. IV, 2008; Grimm, 
1998). In addition to the specific shelf life indicated by the 
manufacturer, some medications prepared in the pharmacy or the 
ward must follow the limits set up by the different 
pharmacopoeias, definitions such as ‘freshly prepared’ (use within 
24 hours of preparation) or ‘recently prepared’ (can be used for up 
to four weeks if stored at 15–25°C) (International Council for 
Harmonization Expert Working Group, 2009). For new drugs, it is 
normal practice to grant only a two-year expiry date when the 
product is first registered. This is based on satisfactory one-year 
long-term and six-month accelerated stability data (Bentley, et al. 
2015). The expiry date for third and later years is allowed only on 
production of real-time data for the subsequent years (Bentley et 
al., 2015). Most pharmaceutical products are characterized by one 
shelf life. However, in some cases a product may have a shelf life 
before constitution and another after opening (e.g. reconstituted 
antibiotics suspensions or injection, or eye preparations) (Bentley 
et al., 2015). Chemical kinetics refers to the rate of chemical 
change during a chemical reaction (Charde, 2014).  
The Mean Kinetic Temperature (MKT) is the single 
calculated temperature at which the total amount of degradation 
over a particular period is equal to the sum of the individual 
degradations that would occur at various cycles of higher and 
lower temperature (Charde, 2014). It is an isothermal storage 
temperature that simulates the non-isothermal effects of storage 
temperature variation (Charde, 2014). The MKT takes into account 
seasonal and daily temperature variations during a year. It 
expresses the cumulative thermal stress undergone by a product at 
varying temperatures during storage and distribution (Charde, 
2014; Bottand Oliveira, 2009).  
As world populations age, patients may require 
assistance in medication adherence and residential home staff may 
require support in managing their residents’ medications (NiDirect 
Government Services, 2017). As medication use increases with 
advancing age, nursing/residential homes rely on pharmacy 
services to support their aging residents (Edirisinghe, 2015). 
Monitored dosage systems (MDS) and medicine compliance aids 
(MCA) or dose administration aids (DAA) have been supplied to 
improve patient adherence with prescribed medications for those 
having difficulties managing their medications (The international 
pharmacopoeia, vol. 5, 2013). Those aids are prepared and 
supplied by pharmacists. There is ongoing debate about drug 
stability in MDS, MCA and DAA (Akerele and Ukoh, 2011) Since 
there is limited short-term stability data for medications in MCAs 
(Akerele and Ukoh, 2011). In Australia, DAAs are commonly used 
for older patients and for Indigenous Australians living in remote 
communities. 
 
AIM 
The aim of this study was to investigate the effect of a 
tropical environment on pharmaceutical preparations in original 
(control) and repackaged containers. 
 
METHODS AND DESIGN 
 
This was a preliminary study to explore the stability and 
sterility of pharmaceuticals stored in a tropical environment. Using 
a temperature and humidity controlled cabinet, the study simulated 
the weather in Darwin NT Australia in the wet season at 30°C, 
80% RH (Figures 1 and 2), which is routinely seen in the houses 
and buildings where air-conditioning is not available or when the 
patient is living outdoors and medication is directly exposed to 
heat, humidity, direct sunlight, soil or rain (e.g., Indigenous 
Australians living in remote communities). This study tested the 
stability of a range of pharmaceuticals through quantifying the 
amount of API through absorbance spectrophotometry, the 
changes in physical characteristics such as appearance, 
disintegration, hardness and pH; and the surface microbiological 
growth after exposure to the study prescribed heat and humidity 
form the supplier for up to 24 weeks.  
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All testing was conducted at Charles Darwin University 
laboratory. The equipment used, consumables and personal 
protective equipment are listed in table 1. 
The study was designed and conducted over three phases 
–Phase 1: preparation of material and workplace, Phase 2: creation 
and validation of the of the absorbance calibration curves, baseline 
microbial  growth,  physical  appearance,  pH and re-packaging  of 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
samples, Phase 3:testing stability, microbial growth, physical 
appearance and pH after exposure to heat and humidity. Eleven of 
the medications most commonly prescribed for the treatment of 
chronic disease, were selected.  
Each medication product tested was from a single batch 
for all samples (Table 2).The absorbance peak for each drug was 
determined from the literature (Table 3). 
 
 
Fig. 1: Average daily 9 am relative humidity in Australia (Image Source: Bureau of Meteorology, Australia). 
 
 
 
Fig. 2:  Average daily 9 am temperature in Australia (Image Source: Bureau of meteorology, Australia). 
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Table 1: Equipment and material.   
Purpose Type Supplier 
Equipment  A pH meter TPS Instruments, Brisbane. 
 Temperature and Humidity Chambers TCH-150 and TCH-460, Thermoline Scientific Equipment.  
 Tablet disintegration apparatus Electrolab. 
 UV spectrophotometer UV-Vis spectrophotometer (Model U-1100), Hitachi Corporation Ltd. 
 Incubator Labec Laboratory Equipment. 
 Microscope  Olympus 
 Colony counter Gallenkamp 
 Tablet Hardness tester Model:EH01, Oclas Luggage 
 Fridge Thermoline Scientific Equipment 
Consumable Culture media plates (Nutrient agar and Sabouraud agar plates). ThermoFisher Scientific 
 Swabs, Multigate Medical Products Swabs, Multigate Medical Products 
 Saline, Baxter 10 ml sachets Saline, Baxter 10 ml sachets 
 Reverse osmosis water Enware 
 Blister packs Medico-Pack and Webster-Pak™ 
 Bottles  Sarstedt 
Personal protective 
equipment 
Gloves, sterile, powder and latex free Mediflex 
 Safety glasses  Prosafe 
 Two-way filter Face mask Livingstone 
 Lab coat  Hard Yakka 
 
 
Table 2: Medication procurement information. 
Drug Manufacturer Strength and Formulation Batch Number Expiry Date AUST-R Number 
Amiodarone GenRx 200 mg tablets E484 April 2016 80768 
Amlodipine Apotex Private Ltd 200 mg tablets MC2450 September 2017 135125 
Aspirin Mayne Pharma 100 mg tablets 995528 August 2016 194209 
Atorvastatin Apotex Private Ltd 80 mg tablets 33619 December 2015 153729 
Gliclazide GenRx 80 mg tablets KW1494 March 2016 80084 
Ibuprofen Abbott Australasia Private Ltd 400 mg tablets 49961PC December 2017 80659 
Irbesartan Apotex Private Ltd 50 mg tablets 1405002456 March 2017 213310 
Metformin Apotex Private Ltd 500 mg tablets ACN4016 December 2016 176509 
Paracetamol Apotex Private Ltd 500 mg tablets X40201 February 2016 156815 
Prednisolone Nova Pharmaceuticals Private Ltd 5 mg tablets PY54008 April 2017 13469 
Sodium Valproate Winthrop 200 mg tablets E002 December 2017 125620 
 
 
 
 
Table 3: Tablet repacks for stability and microbiological testing. 
Time line Original and repackaged dose administration pack 
Day 1 - on purchase 
Create absorbent/concentration curve and establish physical 
appearance (photographs and in word description), pH and 
baseline microbial count 
One set of three tablets of all 11 medications in original manufacturer’s container  
 
Re-pack of samples for stability and microbial testing for 
duration of 24 weeks 
Four sets of three tablets of all 11 medications repackaged in bottles and in separate blisters in dose 
administration aid packs (Webster-Pak™& Medico-Pak™) 
                Incubated in humidity and temperature chamber 
Week 1 
Test for stability, microbial growth, physical appearance 
and pH  
Three tablets out of an original pack (one tablet for each) x 11 medications 
Three tablets (one tablet for each) in bottles x 11 medications 
Three tablets (one tablet for each) in Webster-Pak™ x 11 medications 
Three tablets (one tablet for each) in MedicoPak™ x 11 medications 
Week 2 
Test for stability, microbial growth, physical appearance 
and pH 
Three tablets out of an original pack (one tablet for each) x 11 medications 
Three tablets (one tablet for each) in bottles x 11 medications 
Three tablets (one tablet for each) in Webster-Pak™ x 11 medications 
Three tablets (one tablet for each) in MedicoPak™ x 11 medications 
Week 4 
Test for stability, microbial growth, physical appearance 
and pH 
Three tablets out of an original pack (one tablet for each) x 11 medications 
Three tablets (one tablet for each) in bottles x 11 medications 
Three tablets (one tablet for each) in Webster-Pak™ x 11 medications 
Three tablets (one tablet for each) in MedicoPak™ x 11 medications 
Month 3 
Test for stability, microbial growth, physical appearance 
and pH 
Three tablets out of an original pack (one tablet for each) x 11 medications 
Three tablets (one tablet for each) in bottles x 11 medications 
Three tablets (one tablet for each) in Webster-Pak™ x 11 medications 
Three tablets (one tablet for each) in MedicoPak™ x 11 medications 
Month 6 
Test for stability, microbial growth, physical appearance 
and pH 
Three tablets out of an original pack (one tablet for each) x 11 medications 
Three tablets (one tablet for each) in bottles x 11 medications 
Three tablets (one tablet for each) in Webster-Pak™ x 11 medications 
Three tablets (one tablet for each) in MedicoPak™ x 11 medications 
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In addition to tablets left in their original containers as 
control undisturbed but labeled as control, repackaged samples 
were packed according to good pharmaceutical manufacturing 
practice for the testing sequence showing in table 4. For the 
purpose of this paper “original container” refers to the control 
where all results will be compared to. 
The method was validated by using the specified method 
on the batched will be used against two different batches of each 
product, the results were the same for the three batches and also 
matched the products manufacturer specifications for API content 
and physical and chemical characteristics and appearance. 
Spectrophotometric calibration curves for the chosen 
medications were developed and validated on Day-1.  
The products from the original containers (control) were 
tested for appearance, hardness, pH, content of API and for 
microbiological contamination. As soon as the medications were 
repackaged, they were placed inside the temperature and humidity 
chamber at 30 °C and 80% RH.  A swabbing technique was used 
to test for microorganisms. The enumeration was done on the outer 
and inner surface of all four types of packs (original, bottle, 
Webster-Pak™ and Medico-Pak™) and tablets used in this study 
at regular time intervals using a commercially available swab. 
They were then transferred to the both nutrient agar and 
sabouraud agar plates. The plates were pre-marked with all 
required information such as date and samples details. Nutrient 
agar plates were incubated for 24 hours for bacterial growth in an 
incubator at 37°C, while sabouraud agar plates were incubated at 
25±2°C for 72 hours for fungal growth detection in an inoculation 
hood. Typical colonies of microbial growth on plates were counted 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
at the end of the incubation period with the aid of a Stuart™ 
colony counter. This procedure was followed for all the samples. 
Gram staining was used as part of the identification process. 
 
RESULTS 
 
Stability testing results 
Control and baseline 
Sampling and testing was conducted on Day 1, as soon as 
the products were received from the supplier. Table 5 shows the 
data used to establish the absorption/concentration curve for                
all 11 medications tested at concentrations of 100%, 75%, 50% 
and 25%. 
 
Table 5: Standard: Absorption/concentration data. 
Drug λ max* 100% 75% 50% 25% 
Amiodarone 305.0 nm 1.90 1.40 1.00 0.60 
Amlodipine 360.0 nm 1.60 1.00 0.70 0.40 
Aspirin 292.0 nm 1.90 1.40 0.70 0.60 
Atorvastatin 246.0 nm 4.60 4.40 4.30 4.20 
Gliclazide 228.0 nm 3.50 3.45 3.44 3.42 
Ibuprofen 254.2 nm 1.80 1.70 1.60 1.50 
Irbesartan 207.0 nm 5.50 4.10 4.00 3.8 
Metformin 234.0 nm 3.53 3.50 3.48 3.45 
Paracetamol 252.8 nm 4.40 4.30 4.20 4.10 
Prednisolone 246.0 nm 3.38 3.36 3.33 3.29 
Sodium Valproate 212.0 nm 4.20 4.00 3.90 3.70 
Note: * λ max for each product was sourced from the product information 
document. 
 
Table 6 presents the physical characteristics for each 
product at baseline on Day-1. All results conformed to the 
Table 4: ʎ max for the 11 selected medications. 
Drug Brand  Λmax (nm) Reference 
Aspirin Astrix 292.0 Simultaneous determination of salicylic acid and acetylsalicylic acid in aspirin delayed-release tablet 
formulations by second-derivative UV-spectrophotometry. Journal of Pharmaceutical and Biomedical 
Analysis. 1998 Dec 1;18(4):871-5. 
Paracetamol Panadol 252.8  Application of a new spectrophotometric method for the analysis of a ternary mixture containing metamizol, 
paracetamol and caffeine in tablets. AnalyticaChimica Acta. 1998 Feb 19;359(1): 93-106. 
Metformin Diabex 234.0  Determination of metformin in pharmaceutical preparations using potentiometry, spectrofluorimetry and 
UV-visible spectrophotometry. AnalyticaChimica Acta. 1999 Jan 4;378(1): 299-311. 
Atorvastatin Atorvastatin 246.0  Application of UV-spectrophotometry and RP-HPLC for simultaneous determination of atorvastatin 
calcium and ezetimibe in pharmaceutical dosage form. Eurasian Journal of Analytical Chemistry. 2006 Sep 
1;1(1). 
Irbesartan  Irbesartan 207.0  Determination of irbesartan in the presence of 
hydrochlorothiazide by derivative spectrophotometry. Journal of Pharmaceutical and Biomedical Analysis. 
2002 Jun 20;29(1):299-305. 
Amlodipine Amlodipine 360.0  Photodegradation monitoring of amlodipine by derivative spectrophotometry. Journal of Pharmaceutical and 
Biomedical Analysis. 2002 Jan 1;27(1):19-24. 
Amiodarone Amiodarone 305.0  Monitoring dissolution rate of amiodarone tablets by a multiple fiber-optic sensor system. Dissolution 
Technologies. 2008 Feb 1;15(1):22. 
Gliclazide Gliclazide 228.0  Simultaneous UV spectrophotometric method for estimation of gliclazide and metformine hydrochloride in 
tablet dosage form. International Journal of ChemTech Research. 2010 Apr 2;(2):813-7. 
Ibuprofen Brufen 254.2  Simultaneous spectrophotometric determination of pseudoephedrine hydrochloride and ibuprofen in a 
pharmaceutical preparation using ratio spectra derivative spectrophotometry and multivariate calibration 
techniques. Journal of Pharmaceutical and Biomedical Analysis. 2004 Feb 18;34(3):473-83. 
Prednisolone Panafcortelone 246.0  Development of simultaneous spectrophotometric method of mesalazine and prednisolone in same dosage 
form. International Journal of Applied Pharmaceutics. 2010;2(4):8-11. 
Sodium 
Valproate 
Epilim 212.0  Valproic acid and sodium valproate: comprehensive profile. Profiles of Drug Substances, Excipients, and 
Related Methodology. 2005 Dec31;32:209-40. 
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published product information for each of the 11 medications 
tested. Tables 7 to 10 contains results for all tested parameters. 
 
Table 6: Standard: Physical characteristics. 
Drug pH Break-point Dissolution  
Amiodarone 4.0 114.2 3:02 sec 
Amlodipine 5.5 95.6 0:36 sec 
Aspirin 3.0 30.0 0:27 sec 
Atorvastatin 7;0 184.0 6:32 sec 
Gliclazide 5.5 146.5 2:38 sec 
Ibuprofen 4.5 166.3 5:80 sec 
Irbesartan 5.5 39.5 4:11 sec 
Metformin 6.5 349.5 11:35 sec 
Paracetamol 6:0 457.2 2:21 sec 
Prednisolone 5.5 39.5 1:38 sec 
Sodium Valproate 6.0 143.7 1:25:53 sec 
 
Metformin 
The largest changes in the API level were seen in the 
repackaged bottles for pH, major changes occurred in 
MedicoPak™ It was not possible to measure hardness (breakpoint) 
SD in metformin tablets beyond four weeks, as the tablets had 
become softened.  After four weeks, major changes in breakpoint 
occurred in the original container. Changes were significant in 
original container after six months (SD= +101.9696). Dissolution 
time also changed from baseline, with significant changes in both 
Webster-Pak™ and MedicoPak™. 
 
Amiodarone 
Most changes in the API level and pH changes were in 
Webster-Pak™. The changes in break point in the original pack 
were more significant than in the repackaged samples were the 
dissolution time changes were significant but similar in both 
repacks and original pack. 
 
Amlodipine 
Most changes in the API level were seen in the Webster-
Pak™. Changes in pH occurred only in MedicoPak™ and bottles. 
The changes in breakpoint for amlodipine were seen in all 
containers where the changes in the dissolution time were 
significant and slightly higher in Webster-Pak™ than all other 
containers. 
 
Aspirin 
Most changes in the API level and pH were seen in the 
repackaged bottles and not in the original containers. The changes 
in the breakpoint in original pack were less significant than in the 
repackaged samples. Dissolution time also changed from baseline; 
the changes in the original pack were less significant than in the 
repackaged samples.   
 
Atorvastatin 
Most changes in the API level were seen in the Webster-
Pak where changes in the pH occurred in all containers. It was not 
possible to measure the breakpoint beyond four weeks as the 
tablets had softened. After the first four week, most changes in 
breakpoint occurred in original container after6 months it was also 
significantly high in the original container. The changes in 
dissolution time in the original pack were less significant than that 
in the repackaged samples. 
 
Gliclazide 
The changes in gliclazide level and pH were most seen in 
the repacks when compared to the original containers. The changes 
in breakpoint were less significant in original bottle than that in the 
repackaged samples in the first four weeks. It was not possible to 
be measured in beyond four weeks, as the tablets softened, but 
after six months it was significantly high in original control 
(SD=7.460362). Dissolution time also changed from that measured 
at baseline; the changes in the original pack were less significant 
than in the repackaged samples. 
 
Ibuprofen 
Most changes in the API level were seen in the Webster-
Pak™. The pH changes occurred in all repackaged samples when 
compared to original pack. The changes in breakpoint the original 
pack and in the repackaged samples were similar and significant. 
Dissolution time changes in the original pack were less significant 
than in the repackaged samples. 
 
Irbesartan 
Most changes in irbesartan stability during the six-month 
study period were seen in the MedicoPak™ where the changes in 
pH occurred mostly in MedicoPak™ and Webster-Pak™. The 
changes in breakpoint for irbesartan original pack were less 
significant than that in the repackaged samples. Dissolution time 
changes in the original pack were less significant than in the 
repackaged samples.  
 
Paracetamol 
The changes in paracetamol stability and pH after six-
month study period were seen in all containers. While the tablets 
did not soften, they had high moisture content after Week 4 
resulting in similar and significant changes in the breakpoint in all 
packs. Dissolution time changes in the original pack were less 
significant than in the repackaged samples.  
 
Prednisolone 
Most of the changes in prednisolone stability during the 
six-month study period were seen in the original pack and re-
packed bottles. Similar significant changes for pH and breakpoint 
were significant and occurred in all containers. Dissolution time 
changes in the original pack were less significant than in the 
repackaged samples. 
 
Sodium valproate 
The most changes in the API level were seen in the 
Webster-Pak™ with no change seen in original packs where the 
change in pH occurred in all containers. The change in breakpoint 
for sodium valproate were significant in all containers. It was not 
possible to measure beyond two weeks as the tablets softened. 
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Dissolution time changes in the original pack were less significant 
than in the repackaged samples. Dissolution rate was not possible 
to be measure beyond two weeks as the tablets softened and 
disintegrated.  
 
Microbiology investigation 
As soon as the products were received from the supplier 
on Day 1, a sterile spreader was used to swab the inside and 
outside of the original container and the tablet surface, and then 
used to distribute the inoculum over the surface of already 
prepared culture plates. Two types of plates were used – nutrient 
agar plates for bacteria detection and Sabouraud Agar plates for 
fungus detection. An incubation period of 24 hours for nutrient 
agar plates and 72 hours for sabouraud agar plates was selected. 
There was a bacterial growth detected on the paracetamol 
container, and on the metformin and sodium valproate original 
boxes. There was also some fungal growth detected on the 
amiodarone, gliclazide, metformin, paracetamol and prednisolone 
original containers. 
After seven days in the temperature and humidity 
controlled chamber, the tablets and their containers were swabbed 
and cultured. There was bacterial growth detected on and in the 
paracetamol container and on the metformin and sodium valproate 
original packs. There was also some fungal growth detected on the 
amiodarone, gliclazide, metformin, paracetamol and prednisolone 
original containers. There was bacterial growth detected on and/or 
in the repackaged bottles for amiodarone, atorvastatin, metformin, 
paracetamol and sodium valproate. There was also fungal growth 
detected on the amiodarone, gliclazide, metformin, paracetamol 
and prednisolone repackaged bottles and on the ibuprofen tablet 
surface. 
There was bacterial growth detected on and in the 
Webster-Pak™ for paracetamol, amiodarone, atorvastatin, 
irbesartan, metformin and sodium valproate, and there was also 
growth on the gliclazide tablet surface. There was fungal growth 
detected on the amiodarone, gliclazide, metformin, paracetamol 
and prednisolone Webster-Pak™ and on the ibuprofen and sodium 
valproate tablet surfaces. There was bacterial growth detected on 
and in the MedicoPak™ for amiodarone, atorvastatin, irbesartan, 
paracetamol, metformin and sodium valproate, and growth on the 
gliclazide tablet surface. There was also fungal growth detected on 
the amiodarone, gliclazide, metformin and prednisolone 
MedicoPak™ and on the ibuprofen and sodium valproate tablet 
surfaces. 
After 14 days in the temperature and humidity controlled 
chamber the tablets and their containers were swabbed and 
cultured. There was bacterial growth detected on and in the 
paracetamol container and on the sodium valproate original packs. 
There was also some fungal growth detected on the amiodarone, 
gliclazide, metformin and paracetamol original containers. There 
was bacterial growth detected on and in the aspirin, irbesartan, 
paracetamol and sodium valproate repackaged bottles and on the 
amiodarone tablet surface. There was also fungal growth detected 
on the aspirin, irbesartan, paracetamol and prednisolone 
repackaged bottles and on the amiodarone, gliclazide and sodium 
valproate tablet surfaces. 
There was bacterial growth detected on and in the 
Webster-Pak™ for aspirin, paracetamol, amiodarone, gliclazide, 
irbesartan and sodium valproate, there was no growth on the tablet 
surfaces. There was also fungal growth detected on the 
amiodarone, aspirin, gliclazide, irbesartan, metformin and 
prednisolone Webster-Pak™ and on the amlodipine and 
paracetamol tablet surfaces. There was bacterial growth detected 
on and in the MedicoPak™ for amiodarone, aspirin, gliclazide, 
atorvastatin, irbesartan, paracetamol and sodium valproate, there 
was no growth on tablet surfaces. There was also fungal growth 
detected on the amlodipine, ibuprofen, metformin and 
prednisolone MedicoPak™ and on the sodium valproate tablet 
surfaces. 
After 28 days in the temperature and humidity controlled 
chamber the tablets and their containers were swabbed and 
cultured. There was bacterial growth detected on and in the 
amiodarone, paracetamol, aspirin and sodium valproate original 
containers. There was also fungal growth detected on the 
amiodarone, amlodipine, atorvastatin, metformin and prednisolone 
original containers (control) and on the irbesartan tablet surface. 
There was bacterial growth detected on and in the amiodarone, 
aspirin, gliclazide, irbesartan, paracetamol and sodium valproate 
repackaged bottles. There was also fungal growth detected on the 
gliclazide and paracetamol repackaged bottles and on the 
amiodarone, aspirin, irbesartan and sodium valproate tablet 
surfaces. There was bacterial growth detected on and in the 
Webster-Pak™ for aspirin, amiodarone, gliclazide, ibuprofen, 
metformin, prednisolone and sodium valproate; there was no 
growth on the tablet surfaces. There was also fungal growth 
detected on the amiodarone, aspirin, gliclazide, ibuprofen, 
metformin and sodium valproate tablet surfaces and on the 
prednisolone Webster-Pak™. There was bacterial growth detected 
on and in the MedicoPak™ for amlodipine, aspirin, gliclazide, 
irbesartan, metformin, prednisolone and sodium valproate, there 
was no growth on tablet surfaces. There was also fungal growth 
detected on the amlodipine, aspirin, gliclazide, ibuprofen, 
metformin, prednisolone and sodium valproate packed in 
MedicoPak™ on the surface of the tablets. 
After three months in the temperature and humidity 
controlled chamber the tablets and their containers were swabbed 
and cultured. There was bacterial growth detected on and in the 
atorvastatin, paracetamol, irbesartan and sodium valproate original 
containers. There was also fungal growth detected on the 
amiodarone, gliclazide, ibuprofen and prednisolone original 
containers. There was bacterial growth detected on and in the 
amiodarone, amlodipine, atorvastatin, gliclazide, irbesartan, 
metformin, prednisolone and sodium valproate repackaged bottles. 
There was also fungal growth detected on the amlodipine, 
atorvastatin, gliclazide and ibuprofen, metformin, prednisolone 
and sodium valproate tablet surfaces in the repackaged bottles. 
There was bacterial growth detected on and in the Webster-Pak™ 
for amlodipine, aspirin, gliclazide, irbesartan, metformin, 
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prednisolone and sodium valproate, there was no growth on the 
tablet surfaces. There was also fungal growth detected on the 
aspirin, gliclazide, ibuprofen, metformin, prednisolone and sodium 
valproate packed in Webster-Pak™ on the surface of the tablets. 
There was bacterial growth detected on and in the MedicoPak™ 
for amlodipine, gliclazide, atorvastatin, metformin, prednisolone 
and sodium valproate; there was no growth on tablet surfaces. 
There was also fungal growth detected on the amiodarone, 
amlodipine, atorvastatin, gliclazide, ibuprofen, metformin, 
prednisolone and sodium valproate packed in MedicoPak™ on the 
surface of the tablets. After six months in the temperature and 
humidity controlled chamber the tablets and their containers were 
swabbed and cultured. There was bacterial growth detected on 
and/or in the amiodarone and amlodipine original containers. 
There was also fungal growth detected on the aspirin, gliclazide, 
paracetamol and prednisolone original containers. There was 
bacterial growth detected on and in the amlodipine, aspirin, 
ibuprofen, metformin, prednisolone and sodium valproate 
repackaged bottles, there was bacterial growth on irbesartan tablet 
surface. There was also fungal growth detected on the gliclazide 
and metformin on the bottle surface and there was fungal growth 
on the amlodipine, atorvastatin, ibuprofen, metformin, 
prednisolone and sodium valproate tablet surfaces in the 
repackaged bottles. There was bacterial growth detected on and in 
the Webster-Pak™ for aspirin, amlodipine, ibuprofen, metformin, 
prednisolone and sodium valproate, and there was bacterial growth 
on the irbesartan tablet surface. There was also fungal growth 
detected on the amlodipine, atorvastatin, ibuprofen, metformin, 
prednisolone and sodium valproate packed in Webster-Pak™ on 
the surface of the tablets and on the amlodipine and on the 
Webster-Pak™ for gliclazide and paracetamol. There was bacterial 
growth detected on and in the MedicoPak™ for metformin, 
paracetamol and sodium valproate; there was no growth on tablet 
surfaces. There was also fungal growth detected on the 
amiodarone, metformin, paracetamol and prednisolone 
MedicoPak™ outside surface. 
 
DISCUSSION 
The findings from this study can be used as a baseline for 
further investigations. This study was carried out on frequently 
prescribed medicines in immediate (traditional) release tablet 
formulations that are used for cardiovascular diseases, diabetes, 
arthritis and respiratory conditions such as COPD (chronic 
obstructive pulmonary disease) or asthma. The 11 medicines 
chosen were aspirin, paracetamol, metformin, atorvastatin, 
irbesartan, amlodipine, amiodarone, gliclazide, ibuprofen and 
prednisolone.  
 
Active pharmaceutical ingredient stability and physical 
changes 
The WHO guidelines of 1998recommend that the storage 
labeling statement should be: Store at 25 °C; excursions permitted 
to 15–30 °C (42). If storage remains within the manufacturer’s 
recommended range, the proposed shelf life can be maintained. 
This study investigated the stability of pharmaceuticals stored in a 
tropical environment where heat and humidity exceeds that 
described by manufacturers, and in many occasions room 
temperature exceeds 30°C, especially in the housing of lower 
socioeconomic patients where air-conditioning is not available. 
Additionally, when medication is exposed to these conditions (heat 
and humidity) and in many cases, directly exposed to the sun, soil 
or rain (if the patient is homeless or living outdoors) can also 
compromise the physical characteristics of the tablets.  
The study tested the stability of the medications through 
quantifying the amount of API after exposure to heat and humidity 
from seven days to 24 weeks. The study also measured any change 
in appearance, dissolution and disintegration of the medications in 
both the manufacturer’s original container and in the repackaged 
DAAs or bottles. Although there are few studies on the stability 
and therefore the efficacy and safety of medicines during packing 
and storage, and consequently little data, this study provides new 
evidence of the stability of enteric coated sodium valproate when 
repackaged in DAAs. It is important however, that DAAs are 
stored in a cool, dry place protected from light, for example inside 
lockable chambers. Monitoring the integrity of DAAs throughout 
the usage period is recommended, since DAAs may be subjected 
to a reasonable amount of handling, inadequate sealing due to 
change in the glue effectiveness in the hot and humid environment 
and accidental puncture of the blister seals, which may further 
increase the possibility of the exposure to intensive levels of heat 
and humidity that exceeds the manufacturer’s recommendations. 
Baseline testing indicated that the starting product met all 
parameters as indicated in the drug product information and the 
Pharmaceopeial limits.  The current literature on the effect of 
temperature on hardness of organic materials indicates that an 
increase in temperature affects the sucrose used in coating tablets. 
The effect on coating was found to reduce the indentation hardness 
of the tablets (Olusanmi, 2010). The increase in temperature and 
humidity may also increase the permeability of the PVC bottles or 
sheets used to make the blister packs which can also affect the 
tablet hardness due to moisture absorption (Olusanmi, 2010). The 
increase in hardness due to loss of moisture is further accelerated 
at temperatures greater than room temperature (Olusanmi, 2010).  
Water absorption increases when the temperature 
exceeds 23 °C for 24 hours, thermal conductivity increases when 
the temperature exceeds 50°C and thermal diffusivity also 
increases when the temperature exceeds 50°C (Olusanmi, 2010). 
In this study, a temperature of 30 °C and humidity of 80% RH 
were used, which affected most measured parameters; however, 
some were affected more than others. Similar results were reported 
by another study where the authors found that temperature and 
humidity reduced both the hardness and fracture toughness of 
aspirin (Olusanmi, 2010). In this current study, while changes 
occurred in the original pack, they were less significant than that in 
the repackaged samples, where bottles had the most significant 
change. Hosny’s (1999) study compared the stability of 
indomethacin tablets under different combinations of temperature 
and RH (30 °C/92.9% RH, 40°C/79.5% RH and 50°C/65% RH for 
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16 weeks) and tested at two, four, eight, 12 and 16 weeks, where 
in this study fixed temperature and RH (30°C/80% RH) were used 
and stability and physical characteristics of tablets were tested at 
intervals of one, two, and four weeks, then after three and six 
months in four different packaging materials. Hosny (1999) 
measured tablet weight, which was not measured in this current 
study (Olusanmi, 2010).  
Hosny (1999) found that the tablet’s mean weight 
significantly increased at 30°C/98% RH, when compared to 
40°C/79.3% RH, and 50°C/65% RH, and proportional hardness 
was reduced – becoming zero at 30°C/98% RH and 92.9% RH, 
which corresponds to the results from this current study at three-
month and six-month testing. All 11 tested medications underwent 
changes (reduction) in hardness in their original containers, except 
aspirin and paracetamol that remained unchanged. In the 
repackaged bottles, Webster-Pak™ and MedicoPak™, aspirin and 
paracetamol remained the same, while amiodarone, amlodipine, 
ibuprofen, irbesartan and prednisolone reduced, and atorvastatin, 
gliclazide, metformin and sodium valproate became zero.  
The API amount measured at baseline remained 
unchanged for gliclazide  and  metformin,  with a  changed  SD  of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
between 0.070 (amlodipine) and 0.636 in atorvastatin (Table 7) in 
all containers. The pH also changed from baseline to six months, 
with the most significant change seen in metformin; however, 
there were no other studies found to compare this finding to (Table 
8). Hosny (1999) found that tablets stored at 30°C with 98% and 
92% RH showed an increase in disintegration time (Hosny, 1999). 
The moisture uptake resulted in an increase in tablet weight, a 
decrease in tablet hardness and faster tablet dissolution rate 
(Hosny, 1999). The results for the repackaged containers were 
similar to the results of this current study, where amiodarone had 
the most significant change.  No changes to tablet appearance were 
seen during the first 28 days. In week four; sodium valproate 
became soft and disintegrated in almost all repackaged containers. 
Table 9 shows the disintegrated tablets in a Webster-Pak™. By the 
third month, samples of atorvastatin, gliclazide and metformin also 
were disintegrated. The results are comparable to that of Hosny 
(1999).  These research findings highlight the need for storing 
DAAs in controlled environments for those patients living in hot 
and humid climates. Healthcare professionals can play an 
important role in advising patients, caregivers and other members 
of the healthcare team on the stability of medications and the 
importance of packaging, storing and using them correctly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7: Change in active pharmaceutical ingredient absorbance from baseline to six months. 
Drug Absorbance at baseline Absorbance at six months SD 
Amiodarone 1.9 1.7 0.141421 
Amlodipine 1.6 1.5 0.070711 
Aspirin 1.9 1.4 0.353553 
Atorvastatin 4.6 3.7 0.636396 
Gliclazide 3.5 3.5 0 
Ibuprofen 1.8 1.6 0.141421 
Irbesartan 5.5 5.3 0.141421 
Metformin 3.6 3.6 0 
Paracetamol 4.4 3.6 0.565685 
Prednisolone 3.38 3.7 0.226274 
Sodium Valproate 4.2 4.0 0.141421 
 
Table 8: Change in pH from baseline to six months. 
Drug Baseline Original Bottle Webster-Pak™ Medico-Pak™ SD 
Amiodarone 40 4.5 5.0 5.0 4.5 0.41833 
Amlodipine 5.5 5.0 5.5 5.5 5.0 0.2738613 
Aspirin 3.0 4.0 4.0 4.0 4.0 0.4472136 
Atorvastatin 7.0 6.0 6.5 6.5 6.0 0.41833 
Gliclazide 5.5 5.5 6.0 6.0 5.5 0.2738613 
Ibuprofen 4.5 5.0 5.0 5.0 5.0 0.2236068 
Irbesartan 5.5 5.5 6.0 6.0 6.0 0.2738613 
Metformin 6.5 6.5 5.5 5.5 5.5 0.5477226 
Paracetamol 6.0 6.5 6.5 6.5 6.0 0.2738613 
Prednisolone 5.5 5.5 6.0 6.0 6.0 0.2738613 
Sodium Valproate 6.0 6.5 6.5 6.5 6.0 0.2738613 
 
Table 9: Dissolution time from baseline to six months. 
Drug Baseline Original Bottle Webster-Pak™ (sec) Medico-Pak™ (sec) SD 
Amiodarone 3:02 7:54 8:34 8:44 8:44 0.102558889 
Amlodipine 0:36 3:35 3:44 3:54 3:54 0.059494884 
Aspirin 0:27 4:05 5:23 5:43 5:43 0.093291575 
Atorvastatin 6.:32 10:09 10:25 10:35 11:05 0.016369849 
Gliclazide 2:38 4:34 7:04 6:54 7:45 0.088791179 
Ibuprofen 5:08 7:43 9:56 11:08 9:05 0.095985437 
Irbesartan 4:11 6:19 6:35 6:40 6:08 0.042697322 
Metformin 11:35 15:03 14:35 14:45 14:45 0.060039532 
Paracetamol 2:21 3:09 5:20 5:28 5:45 0.0645359 
Prednisolone 1:38 3:48 5:32 5:35 5:43 0.073416606 
Sodium Valproate 1:25:53 1:11:23 0 0 0 0.030120335 
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Microbiology investigation 
Akerele et al. (2002) concluded that on microbiological 
examination of tablets dispensed from large containers in hospitals 
and community pharmacies there was growth of both aerobic 
bacteria and fungi detected (Gunar, 2011). The aerobic organisms 
were mainly Bacillus species and Streptococci (Akerele and Ukoh, 
2011).  
The frequent occurrence of enterobacteria among 
ascorbic acid and folic tablets from hospital and community 
pharmacies were compared (Akerele and Ukoh, 2011). Among the 
fungi encountered with the tablets were Microsporum spp, 
Penicillium spp, Trichophyton, Aspergillus, Cephalosporium and 
Epidermophyton (Akerele and Ukoh, 2011). In this current study, 
there was contamination by microorganisms  in both  the  original  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
and repackaged containers. However, after one week, growth was 
found on both the outer and inner surface of all containers, 
including the original pack. Growth on the surface of the tablets 
was not consistent, and might have been related to the packing of 
that container rather than the batch. In Week 2 there was bacterial 
growth on the amiodarone tablet surface, but it was not found 
again. Similarly, bacterial growth was found for gliclazide in 
Week 1, and sodium valproate and irbesartan in month 6. 
Occurrences of bacterial growth were apparent in all types of 
packaging used for re-packaging.  Fungal growth was different; it 
was seen on and in all repackaged containers, and on the surface of 
all tablets from Week 4 to Month 6, which further indicates the 
greater effect of humidity and temperature together, rather than 
humidity alone.  
Table 10: Changes after 6 months in the controlled temperature and humidity cabinet (unless otherwise specified). 
Medications 
Comments Absorbance 
SD 
pH 
SD 
Breakpoint 
SD 
Dissolution time 
SD 
Metformin 
Original pack 0.044721 0.273861 73.92789* 0 
Bottle 0.054772 0.273860 69.46222* 0 
Webster-Pak™ 0 0.447213 66.39528* 0.113376 
MedicoPak™ 0.044721 0.447214 60.57953* 0.111385 
Amiodarone 
Original pack 0.04 0 19.29045 0.110189 
Bottle 0.101980 0.244949 10.16065 0.131130 
Webster-Pak™ 0.12 0.400000 9.321052 0.134800 
MedicoPak™ 0.063246 0 10.11002 0.133336 
Amlodipine 
Original pack 0 0 32.01273 0.055649 
Bottle 0.114018 0.223607 24.36458 0.068461 
Webster-Pak™ 0.151658 0 24.81929 0.073573 
MedicoPak™ 0.114018 0.223607 24.59263 0.0722 00 
Aspirin 
Original pack 0 0 24.67766 0.073186 
Bottle 0.114018 0.447214 27.82490 0.108683 
Webster-Pak™ 0.089443 0.447214 25.69431 0.111006 
MedicoPak™ 0.114018 0.447214 26.19248 0.109988 
Atorvastatin 
Original pack 0.044721 0.223607 15.76166* 0.070674 
Bottle 0.141421 0.447214 8.834214* 0.095772 
Webster-Pak™ 0.194936 0.273861 5.221430* 0.114725 
MedicoPak™ 0.089443 0.418330 5.164301* 0.125603 
Gliclazide 
Original pack 0 0 4.990324* 0.041701 
Bottle 0.089443 0.223607 3.143247* 0.092909 
Webster-Pak™ 0.109545 0.353553 3.557152* 0.095125 
MedicoPak™ 0.054772 0.223607 3.857460* 0.107431 
Ibuprofen 
Original pack 0.044721 0.273861 32.49441 0.052040 
Bottle 0.122474 0.273861 30.61723 0.102585 
Webster-Pak™ 0.181659 0.273861 22.18889 0.119976 
MedicoPak™ 0.083666 0.273861 24.93538 0.106582 
Irbesartan 
Original pack 0.089443 0 0.581378 0.044483 
Bottle 0.134164 0 3.401176 0.064780 
Webster-Pak™ 0.698570 0.223607 3.105238 0.073554 
MedicoPak™ 0.831865 0.353553 3.426368 0.067940 
Paracetamol 
Original pack 0.089443 0.223607 34.15804 0.016667 
Bottle 0.194936 0.353553 41.47804 0.062867 
Webster-Pak™ 0.044721 0.353553 61.35852 0.075129 
MedicoPak™ 0.178885 0.223607 54.23088 0.080842 
Prednisolone 
Original pack 0.178885 0.223607 8.707353 0.045166 
Bottle 0.089443 0.223607 4.977148 0.083520 
Webster-Pak™ 0.260768 0.223607 6.069761 0.091492 
MedicoPak™ 0.089443 0.223607 5.996916 0.094204 
Sodium valproate 
Original pack 0 0.223607 1.555635** 0.009821** 
Bottle 0.089443 0.273861 4.454773** 0.000581** 
Webster-Pak™ 0.271993 0.273861 2.828427** 0.000131** 
MedicoPak™ 0.054772 0.223607 6.010408** 0.000246** 
*Duration of four weeks 
**Duration of two weeks 
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Limitations 
 Due to the short time of the master by research candidature, 
there were some limitations imposed on the methodology:  
 A small sample of medications was used to reduce the cost 
(n=11). 
 There was one set of temperature and RH used (30◦C/80% RH) 
instead of different combinations of temperature and RH at the 
set time of testing to replicate previous studies (Hosny, 1999). 
 The study did not include capsules or other specialized release 
tablets such as sublingual or wafers. 
 This preliminary study has demonstrated that products stored in 
tropical conditions changed in their characteristics and also 
gained microbial contamination during the processing.  Further 
research is required to fully characterize the problem. 
 
CONCLUSION 
 
Re-packaging and re-labeling of medications are 
currently common practice for patients on discharge from hospital, 
or for those taking multiple medications that require management 
to avoid patient confusion, often by re-packaging into a DAA. 
Additionally, re-packaging and re-labeling is common practice for 
dispensing all prescriptions in countries where bulk medication 
containers are used. This practice personalize medication for 
individual patients.  
This study contributes meaningful data to current 
practice. The process for determining stability (chemical and 
physical) of pharmaceuticals outside the manufacture container is 
complex because of the various factors that influence the stability 
of pharmaceutical products. However, it is an important area for 
further research because medication should treat a medical 
condition, not create a new problem.     
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